Long-term NSAID use and incident urothelial cell carcinoma in the VITamins and Lifestyle (VITAL) study

Urologic Oncology: Seminars and Original Investigations

Volumn 31, Issue 8, 2013, Pages 1689-1695

  Shih, Cheryl ^a   Hotaling, James M ^a   Wright, Jonathan L ^a,b   White, Emily ^b,c  

^a UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^b USA   (United States)

^c UNIVERSITY OF WASHINGTON   (United States)

Author keywords

Aspirin; Cancer prevention; Nonsteroidal anti inflammatory drugs; Urothelial carcinoma

Indexed keywords

ACETYLSALICYLIC ACID; CELECOXIB; IBUPROFEN; INDOMETACIN; NAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT; PIROXICAM; ROFECOXIB;

ADULT; AGED; ARTICLE; CANCER REGISTRY; CANCER RISK; CORRELATIONAL STUDY; FEMALE; FOLLOW UP; HUMAN; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSPECTIVE STUDY; RISK REDUCTION; SMOKING; TRANSITIONAL CELL CARCINOMA; TREATMENT DURATION;

ASPIRIN; CANCER PREVENTION; NONSTEROIDAL ANTI-INFLAMMATORY DRUGS; UROTHELIAL CARCINOMA;

AGED; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CARCINOMA, TRANSITIONAL CELL; CHEMOPREVENTION; FEMALE; FOLLOW-UP STUDIES; HUMANS; INCIDENCE; LIFE STYLE; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; OUTCOME ASSESSMENT (HEALTH CARE); PROPORTIONAL HAZARDS MODELS; PROSPECTIVE STUDIES; RISK FACTORS; SMOKING; TIME FACTORS; URINARY BLADDER NEOPLASMS; VITAMINS; WASHINGTON;

EID: 84886250806     PISSN: 10781439     EISSN: 18732496     Source Type: Journal    
DOI: 10.1016/j.urolonc.2012.06.001     Document Type: Article

References (28)

1. Jemal A., Siegel R., Xu J., et al. Cancer statistics. CA Cancer J Clin 2010, 2010:277-300.
2. Kaufman D.S., Shipley W.U., Feldman A.S. Bladder cancer. Lancet 2009, 374:239-249.
3. Sievert K.D., Amend B., Nagele U., et al. Economic aspects of bladder cancer: what are the benefits and costs?. World J Urol 2009, 27:295-300.
4. Rostom A., Dubé C., Lewin G., et al. Nonsteroidal anti-inflammatory drugs and cyclooxygenase-2 inhibitors for primary prevention of colorectal cancer: a systematic review prepared for the U.S. Preventive Services Task Force. Ann Intern Med 2007, 146:376-389.
5. Singh-Ranger G., Mokbel K. The role of cyclooxygenase-2 (COX-2) in breast cancer, and implications of COX-2 inhibition. Eur J Surg Oncol 2002, 28:729-737.
6. Okamoto A., Shirakawa T., Bito T., et al. Etodolac, a selective cyclooxygenase-2 inhibitor, induces up-regulation of E-cadherin and has antitumor effect on human bladder cancer cells in vitro and in vivo. Urology 2008, 71:156-160.
7. Steele V.E., Rao C.V., Zhang Y., et al. Chemopreventive efficacy of naproxen and nitric oxide-naproxen in rodent models of colon, urinary bladder, and mammary cancers. Cancer. Prev Res (Phila) 2009, 2:951-956.
8. Kömhoff M., Guan Y., Shappell H.W., et al. Enhanced expression of cyclooxygenase-2 in high grade human transitional cell bladder carcinomas. Am J Pathol 2000, 157:29-35.
9. Shirahama T. Cyclooxygenase-2 expression is up-regulated in transitional cell carcinoma and its preneoplastic lesions in the human urinary bladder. Clin Cancer Res 2000, 6:2424-2430.
10. Zha S., Yegnasubramanian V., Nelson W.G., et al. Cyclooxygenases in cancer: progress and perspective. Cancer Lett 2004, 215:1-20.
11. Castelao J.E., Yuan J.M., Gago-Dominguez M., et al. Nonsteroidal anti-inflammatory drugs and bladder cancer prevention. Br J Cancer 2000, 82:1364-1369.
12. Fortuny J., Kogevinas M., Garcia-Closas M., et al. Use of analgesics and nonsteroidal anti-inflammatory drugs, genetic predisposition, and bladder cancer risk in Spain. Cancer Epidemiol Biomarkers Prev 2006, 15:1696-1702.
13. Fortuny J., Kogevinas M., Zens M.S., et al. Analgesic and anti-inflammatory drug use and risk of bladder cancer: a population based case control study. BMC Urol 2007, 7:13.
14. Genkinger J.M., De Vivo I., Stampfer M.J., et al. Nonsteroidal anti-inflammatory drug use and risk of bladder cancer in the health professionals follow-up study. Int J Cancer 2007, 120:2221-2225.
15. Sørensen H.T., Friis S., Nørgård B., et al. Risk of cancer in a large cohort of nonaspirin NSAID users: a population-based study. Br J Cancer 2003, 88:1687-1692.
16. Daugherty S.E., Pfeiffer R.M., Sigurdson A.J., et al. Nonsteroidal anti-inflammatory drugs and bladder cancer: a pooled analysis. Am J Epidemiol 2011, 173:721-730.
17. White E., Patterson R.E., Kristal A.R., et al. VITamins and lifestyle cohort study: study design and characteristics of supplement users. Am J Epidemiol 2004, 159:83-93.
18. Thun M.J. Beyond willow bark: aspirin in the prevention of chronic disease. Epidemiology 2000, 11:371-374.
19. Tegeder I., Pfeilschifter J., Geisslinger G. Cyclooxygenase-independent actions of cyclooxygenase inhibitors. FASEB J 2001, 15:2057-2072.
20. Takada Y., Bhardwaj A., Potdar P., et al. Nonsteroidal anti-inflammatory agents differ in their ability to suppress NF-κB activation, inhibition of expression of cyclooxygenase-2 and cyclin D1, and abrogation of tumor cell proliferation. Oncogene 2004, 23:9247-9258.
21. Langman M.J., Cheng K.K., Gilman E.A., et al. Effect of anti-inflammatory drugs on overall risk of common cancer: case-control study in general practice research database. BMJ 2000, 320:1642-1646.
22. Pommer W., Bronder E., Klimpel A., et al. Urothelial cancer at different tumor sites: role of smoking and habitual intake of analgesics and laxatives. Results of the Berlin Urothelial Cancer Study. Nephrol Dial Transplant 1999, 14:2892-2897.
23. Cook N.R., Lee I.M., Gaziano J.M., et al. Low-dose aspirin in the primary prevention of cancer: The Women's Health Study: a randomized controlled trial. JAMA 2005, 294:47-55.
24. Wogan G.N., Hecht S.S., Felton J.S., et al. Environmental and chemical carcinogenesis. Semin Cancer Biol 2004, 14:473-486.
25. Badawi A.F., Habib S.L., Mohammed M.A., et al. Influence of cigarette smoking on prostaglandin synthesis and cyclooxygenase-2 gene expression in human urinary bladder cancer. Cancer Invest 2002, 20:651-656.
26. Blumentals W.A., Foulis P.R., Schwartz S.W., et al. Analgesic therapy and the prevention of bladder cancer. Urol Oncol 2004, 22:11-15.
27. Strope S.A., Montie J.E. The causal role of cigarette smoking in bladder cancer initiation and progression, and the role of urologists in smoking cessation. J Urol 2008, 180:31-37. Discussion 37.
28. Ridker P.M., Cook N.R., Lee I.M., et al. A randomized trial of low-dose aspirin in the primary prevention of cardiovascular disease in women. N Engl J Med 2005, 352:1293-1304.